Skip to Main Content

Paper Details

Repurposing FDA approved drugs as radiosensitizers for treating hypoxic prostate cancer.
BMC Urol
3
2021
Author NameAffiliation
Becky A S BibbyUniversity of Manchester, The Christie NHS Foundation Trust
Niluja ThiruthaneeswaranUniversity of Manchester, The Christie NHS Foundation Trust
Niluja ThiruthaneeswaranSydney Medical School, University of Sydney
Lingjian YangUniversity of Manchester, The Christie NHS Foundation Trust
Darragh G McArtQueen's University Belfast
Robert G BristowUniversity of Manchester, The Christie NHS Foundation Trust
Robert G BristowCRUK Manchester Institute and CRUK Manchester Centre
Ananya ChoudhuryUniversity of Manchester, The Christie NHS Foundation Trust
Catharine M L WestUniversity of Manchester, The Christie NHS Foundation Trust
  • 1 - 9

Datasets

Release 1.2